Alendronate Therapy for Osteoporosis
Effectiveness for Fracture Prevention
- The American College of Physicians recommends alendronate as first-line pharmacologic treatment for osteoporosis based on the most favorable balance of benefits, harms, and cost among available therapies 1
- High-quality evidence demonstrates that alendronate significantly reduces hip fractures by 6 fewer events per 1,000 patients treated 1
- Alendronate reduces clinical vertebral fractures by 18 fewer events per 1,000 patients 1
- Alendronate reduces any clinical fracture by 24 fewer events per 1,000 patients 1
- Alendronate reduces radiographic vertebral fractures by 56 fewer events per 1,000 patients 1
- Alendronate reduces vertebral fractures by 47-56% in postmenopausal women with existing fractures 2, 3
Safety Profile
- High-certainty evidence demonstrates no difference in serious adverse events or withdrawals due to adverse events compared to placebo 1
- Mild gastrointestinal symptoms are the most common adverse effects 2
- Osteonecrosis of the jaw has an incidence of 0.01-0.3% in bisphosphonate users, with risk increasing with longer treatment duration 1, 4
- Atypical femoral fractures have an adjusted risk ratio of 3.4 compared to untreated osteoporosis patients 1
Treatment Duration and Monitoring
- Treat osteoporotic patients with alendronate for 5 years initially 1, 2
- Do not monitor bone mineral density during the 5-year treatment period, as BMD changes do not predict fracture reduction benefit 2, 4